secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0001104659-25-061230
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros Pharmaceuticals assigns subsidiary assets (Metuchen, Timm, Pos-T-Vac) to creditor trust
--------------------------------------------------------------------------------

- Effective June 16, 2025, Petros assigned all assets of subsidiaries Metuchen, Timm Medical, and Pos-T-Vac to a third-party fiduciary for benefit of creditors.
- The Vivus License Agreement for Stendra® was terminated March 31, 2025; Petros lost all rights to Stendra in the Licensed Territory.
- Pro forma balance sheet shows stockholders' equity of $8.0M as of March 31, 2025, reflecting deconsolidation, warrant exercises, and redemptions.
- Subsidiaries' operations classified as discontinued; deconsolidation from Petros' balance sheet expected in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465925061230/0001104659-25-061230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465925061230/tm2518572d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-061230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer